Immuneering announced that the U.S. Food and Drug Administration has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering treatment of pancreatic cancer granted FDA orphan status
- 3 Penny Stocks to Watch Now, 9/18/24
- Morning Movers: Boeing slips following Seattle factory workers’ strike
- Immuneering price target raised to $13 from $12 at Chardan
- Immuneering announces initial response data from first five IMM-1-104 patients